Vulvovaginal Candidiasis – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Vulvovaginal Candidiasis – Drugs In Development, 2024 report and make more profitable business decisions.
An excessive growth of yeast in the vagina that results in irritation, a local fungal infection caused by the Candida genus. It is most commonly seen in females in high estrogen states, pregnancy, oral contraceptive use, obesity, diabetes mellitus. It is not considered an STI although it can be transmitted by sexual intercourse.
The Vulvovaginal Candidiasis drugs in development market research report provide comprehensive information on the therapeutics under development for Vulvovaginal Candidiasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Vulvovaginal Candidiasis and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Vulvovaginal Candidiasis | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 13 molecules, with 13 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Vulvovaginal Candidiasis therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Vulvovaginal Candidiasis pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Vulvovaginal Candidiasis treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Cisen Pharmaceutical Co LtdConcerto Biosciences Inc
Female Healthcare Purna
Gedeon Richter Plc
Grupo Ferrer Internacional SA
Jiangsu ProteLight Pharmaceutical & Biotechnology Co Ltd
Matinas BioPharma Holdings Inc
Mycovia Pharmaceuticals Inc
Osel Inc
Profem GmbH
Riptide Bioscience Inc
Sano Chemicals Inc
Satellos Bioscience Inc
Toltec Pharmaceuticals LLC
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Vulvovaginal Candidiasis reports